Fish intake, n-3 fatty acid body status, and risk of cognitive decline: a systematic review and a dose-response meta-analysis of observational and experimental studies
Datum
2022Language
en
Schlagwort
Zusammenfassung
Context: Randomized controlled trials (RCTs) testing supplementation with eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids have failed to provide evidence supporting a suggested inverse association between fish intake and dementia risk. Objective: Dose-response analyses were conducted to evaluate associations between fish intake, all-cause dementia or Alzheimer's Disease (AD), and the effect of EPA/DHA supplementation on cognitive performance. Data Sources: PubMed, Scopus and Web of Science databases were searched for original research evaluating either associations between fish intake and dementia or AD, or the impact of EPA and/or DHA supplementation on the risk of cognitive decline. Data Extraction: Data were collected on study characteristics and methods; number of cases/deaths (for observational studies); categories of exposure; model covariates; risk estimates from the most-adjusted model; type and dosage of supplementation (from RCTs); fatty acid levels in blood; and differences in cognition test results before and after supplementation. Risk of bias was assessed through the ROBINS-E and RoB2.0 tools for observational and experimental studies, respectively. Data Analysis: Weighted mixed-effects models were applied, allowing for the inclusion of studies with 2 levels of exposure. Based on findings with low/moderate risk of bias, fish intake of up to 2 portions (250 g) per week was associated with a 10% reduction (95% confidence interval [CI]: 0.79, 1.02, Ν = 5) in all-cause dementia and a 30% reduction (95% CI: 0.54, 0.89, Ν = 3) in AD risk. Changes in EPA and DHA body status had a positive impact on participants' executive functions, but not on their overall cognitive performance. Conclusion: The protection offered by fish intake against cognitive decline levels off at intakes higher than 2 portions/week and likely relates to the impact of EPA and DHA on the individual's executive functions, although there remain questions about the mechanisms linking the short- and long-term effects. Systematic Review Registration: PROSPERO registration no. CRD42019139528. © 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved.
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
A Preliminary Study on the Feasibility of Using a Virtual Reality Cognitive Training Application for Remote Detection of Mild Cognitive Impairment
Zygouris S., Ntovas K., Giakoumis D., Votis K., Doumpoulakis S., Segkouli S., Karagiannidis C., Tzovaras D., Tsolaki M. (2017)Background: It has been demonstrated that virtual reality (VR) applications can be used for the detection of mild cognitive impairment (MCI). Objective: The aim of this study is to provide a preliminary investigation on ... -
Computerized cognitive rehabilitation for treatment of cognitive impairment in multiple sclerosis: An explorative study
Vilou I., Bakirtzis C., Artemiadis A., Ioannidis P., Papadimitriou M., Konstantinopoulou E., Aretouli E., Messinis L., Nasios G., Dardiotis E., Kosmidis M.H., Grigoriadis N. (2020)In this explorative study, forty-seven patients with relapsing-remitting multiple sclerosis were randomized to a custom 6-week cognitive rehabilitation intervention (n = 23) using the BrainHQTM web-based platform and to a ... -
Cognitive Neurorehabilitation in Acquired Neurological Brain Injury
Messinis L., Kosmidis M.H., Nasios G., Dardiotis E., Tsaousides T. (2019)[No abstract available]